Cancer | Novartis

Media Release
Jun 02, 2023
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Interior Page
ASCO 2023
Landing Page
ASCO Annual Meeting
Media Release
May 11, 2023
Novartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual Meeting
Media Release
Apr 26, 2023
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Media Release
Mar 27, 2023
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Media Release
Dec 05, 2022
Novartis Pluvicto™ shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer
Media Release
Dec 06, 2022
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
Media Release
Dec 13, 2022
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
Media Release
Feb 06, 2023
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Story
Feb 04, 2023
When you think of the word ‘cancer’, what are the first words that spring to mind?
Media Release
Nov 22, 2022
Novartis highlights scientific advances with Kisqali, iptacopan, Scemblix and YTB323 data at SABCS and ASH